EPM sits down with Paul Orange, chief marketing officer at H.E.L Group & Joe Willmot, application leader at H.E.L Group to discuss the company’s customer legacy and how the pharma market has changed since its formation over 30 years ago.
In Profile (Web)
What’s the biggest change you’ve experienced in pharma since the formation of H.E.L?
As H.E.L has been in business for over 30 years, picking just one change is a tough question. However, we have seen the rise of biotherapeutics from an almost zero base. What is an interesting observation, is that the predicted death of small molecule drugs has not taken place. Instead, we see that biopharmaceuticals are finding their own therapeutic niches. These niches are evolving alongside the continued growth of small molecule therapies.
And how have changing trends in the industry impacted H.E.L as a company?
Taking our customer base as a whole, 30 years ago we could not have predicted the importance and speed of battery technology development that we see today. Nor could we have predicted the level of activity in the white biotechnology sector - in particular trying to solve some of the more challenging climate change issues that we face. For us, these changes have meant that our product portfolio has continuously developed to support the changing market.